With the release of the new HBV guidelines, treatment eligibility broadens. This EASL Studio explores how to communicate these changes, support shared decision-making, ensure adherence, and engage patients in ongoing care and clinical trials.

Moderator: Ahmed Elsharkawy 

Faculty: Markus Cornberg, Sital Shah, Thomas Tu, Su Wang

This EASL Studio is supported by Aligos Therapeutics, GSK and Gilead Sciences Europe Ltd . EASL has received no input from Aligos Therapeutics, GSK or Gilead Sciences Europe Ltd with regards to the content of this programme.

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.